Search
for
Sort by
Research 631–660 of 1000+
- Tru9I Variant as a Novel Genetic Marker for Vitamin D Deficiency in Alopecia Areata
- Treatment preferences of adults and adolescents with alopecia areata: A discrete choice experiment
- Recent advances in the genetics of alopecia areata
- Iron Screening in Alopecia Areata Patients May Catch Hereditary Hemochromatosis Early
- Case Report: Successful Treatment of Alopecia Universalis With Tofacitinib and Increased Cytokine Levels: Normal Therapeutic Reaction or Danger Signal?
- Emerging Unconventional Therapies for Alopecia Areata
- A study on the clinical and hormonal profile of patients with hirsutism
- Microneedles along with conventional therapies: An in-depth observational review in alopecia areata treatment
- Off-Label Uses of Abrocitinib: Review of Emerging Therapeutic Applications beyond Atopic Dermatitis
- Patient-reported outcome improvements following scalp hair regrowth among patients with Alopecia Areata: analysis of the ALLEGRO-2b/3 trial
- Tofacitinib Treatment in Patients With Active COVID-19 Infection
- Review of Promising Off-Label Use of Deucravacitinib
- Phytotherapeutic Interventions using Rodent Models of Hair Loss: Current Research and Future Strategy
- Rapid hair regrowth in an alopecia universalis patient with deucravacitinib: A case report
- Hair regrowth in a patient with alopecia universalis and psoriasis vulgaris during deucravacitinib therapy
- Wnt/β-catenin signalling: function, biological mechanisms, and therapeutic opportunities
- SARS-CoV-2 Non-Structural Proteins and Their Roles in Host Immune Evasion
- Alopecia areata: What’s new in the epidemiology, comorbidities, and pathogenesis?
- 3-Deoxysappanchalcone Promotes Proliferation of Human Hair Follicle Dermal Papilla Cells and Hair Growth in C57BL/6 Mice by Modulating WNT/β-Catenin and STAT Signaling
- Treatment options for androgenetic alopecia: Efficacy, side effects, compliance, financial considerations, and ethics
- Long‐term safety and efficacy of ritlecitinib in adults and adolescents with alopecia areata and at least 25% scalp hair loss: Results from the ALLEGRO‐LT phase 3, open‐label study
- Tofacitinib Loaded Squalenyl Nanoparticles for Targeted Follicular Delivery in Inflammatory Skin Diseases
- Patterns of clinical response in patients with alopecia areata treated with ritlecitinib in the ALLEGRO clinical development programme
- Efficacy and safety of tofacitinib therapy in Asian patients with severe alopecia areata
- Whole exome sequencing in Alopecia Areata identifies rare variants in KRT82
- Sustained hair regrowth with continued ritlecitinib treatment through week 48 in patients with alopecia areata with or without early target responses: Post hoc analysis of the ALLEGRO phase 2b/3 trial
- Multimodal roles of transient receptor potential channel activation in inducing pathological tissue scarification
- An outline of SARS-CoV-2 pathogenesis and the complement cascade of immune system
- A Study of Correlation of Alopecia Areata and Metabolic Syndrome in Northwest Indian Population
- Selective Expansion of Tregs Using the IL-2 Cytokine Antibody Complex Does Not Reverse Established Alopecia Areata in C3H/HeJ Mice